In this study, the ability of porous silicon nanoparticles (PSi NPs) to entrap and deliver nitric oxide (NO) as an effective antibacterial agent is tested against different Gram-positive and Gram-negative bacteria. NO was entrapped inside PSi NPs functionalized by means of the thermal hydrocarbonization (THC) process. Subsequent reduction of nitrite in the presence of d-glucose led to the production of large NO payloads without reducing the biocompatibility of the PSi NPs with mammalian cells. The resulting PSi NPs demonstrated sustained release of NO and showed remarkable antibacterial efficiency and anti-biofilm-forming properties. These results will set the stage to develop antimicrobial nanoparticle formulations for applications in chronic wound treatment.
In this study, the ability of porous silicon nanoparticles (PSi NPs) to entrap and deliver nitric oxide (NO) as an effective antibacterial agent is tested against different Gram-positive and Gram-negative bacteria. NO was entrapped inside PSi NPs functionalized by means of the thermal hydrocarbonization (THC) process. Subsequent reduction of nitrite in the presence of d-glucose led to the production of large NO payloads without reducing the biocompatibility of the PSi NPs with mammalian cells. The resulting PSi NPs demonstrated sustained release of NO and showed remarkable antibacterial efficiency and anti-biofilm-forming properties. These results will set the stage to develop antimicrobial nanoparticle formulations for applications in chronic wound treatment.
Wound contamination by bacteria or other microorganisms may cause a delay in or a
deterioration of the healing process [1,2]. Although bacteria are present in most wounds, the body’s immune
defense is generally efficient in overcoming this contamination and supporting
successful healing. However, in some cases, such as diabetic, immunocompromised or
elderly patients, the immune system requires assistance [3-6]. Typical treatments for infection in these cases include antibiotics,
which can be applied directly to the wound or taken orally. In cases of severe
infection, intravenous administration is required to rapidly achieve dosages
sufficient to clear the bacterial load [7,8]. Recently, concerns have arisen over the increased prevalence of
antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus
aureus (MRSA), which is promoted by injudicious antibiotic use [3,9]. Serious and sometimes fatal cases of antibiotic-resistant infections
have occurred in hospitals and community settings [10], and this is developing into an important public health problem [8].Recently, new antibacterial therapeutics based on nanomaterials have emerged for the
treatment of infected wounds [11-14]. For example, mesoporoussilica has been used as a nanocarrier to deliver
antibacterial agents lysozyme and 1-alkylquinolinium bromide ionic liquids in a
controlled manner [15,16]. However, the further development of antibiotic delivering nanoparticles
(NPs) has been hampered by increasing bacterial resistance to conventional
antibiotic candidates for the active agent [3]. In the early 1990s, nitric oxide (NO) was considered as an alternative
antibiotic strategy for a wide range of Gram-positive and Gram-negative bacteria [17,18]. NO is produced by various cells resident in the skin as one of the
natural defenses of the immune system and should therefore prove to be effective
against pathogen invasion while being tolerated by human skin [19]. The mechanism of NO-mediated bactericidal actions is reasonably well
understood [19,20]. A major factor appears to be membrane destruction via lipid peroxidation [9,17].In order to harness the antibacterial power of NO, however, this molecule must be
loaded and trapped in a suitable carrier. NO-loaded silica nanocarriers have been
synthesized using diazeniumdiolate NO donors [9]. The NO loading capacity was directly influenced by NP size [21]. These NPs showed antibacterial efficacy in a time- and
concentration-dependent manner [9,21] and reduced biofilms composed of Gram-positive and Gram-negative bacteria
(≥5 and 2 log reduction, respectively) [22]. In an alternative approach, Friedman and co-workers synthesized
NO-loaded silica nanocarriers using glucose for the thermal reduction of nitrite to
NO [23]. The sustained release of NO from the silica NPs resulted in
antimicrobial and wound-healing properties against cutaneous MRSA and
Acinetobacter baumannii [4,23].Porous silicon (PSi) is a high surface area, high porosity, biocompatible, and
bioresorbable form of silicon widely employed in biomedical applications, including
as NPs [24-28]. The use of PSi NPs avoids the issues of toxicity associated with
silica-derived nanocarriers; further, NP porosity can be easily tuned by
manipulation of current density [29,30]. Thermally hydrocarbonized porous silicon (THCPSi) NPs have remarkable
stability in physiological environments and also show low cytotoxicity in vivo [25]. THCPSi elicits little inflammatory response [25,28]. Small molecular drugs and peptides have been successfully loaded into
and released from THCPSi NPs, with some promising results in the areas of drug
delivery and multimodal bioimaging [24]. Due to these promising properties, we have chosen THCPSi NPs as a
nanocarrier for NO and have explored the antibacterial efficacy of NO-loaded NPs
towards planctonic Escherichia coli, Pseudomonas aeruginosa, and
Staphylococcus aureus and a Staphylococcus epidermidis
biofilm. All of these pathogens can cause primary skin and soft tissue infection [8,31,32]. We also investigated whether the same NPs would be cytotoxic to
fibroblast cells.
Methods
Chemicals and materials
Silicon wafers (boron doped, p+ type, 0.01 to 0.02 Ω cm) were
obtained from Siegert Wafer GmbH (Aachen, Germany). Ethanol (EtOH,
99.6 vol.%) was obtained from Altia Plc. (Porkkalankatu, Finland), and
hydrofluoric acid (HF, 38%) from Merck GmbH (Darmstadt, Germany). Sulfuric acid,
sodium nitrite, Griess reagent,
4-amino-5-methylamino-2′,7′-difluorofluorescein (DAF-FM),
d-glucose, potassium hydroxide, and phosphate-buffered
saline (PBS) tablets were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Tryptic soy broth (TSB; soybean-casein digest) and nutrient agar were purchased
from Thermo-Scientific (Waltham, MA, USA). E. coli (ATCC #25922),
P. aeruginosa (ATCC #27853), S. epidermidis (ATCC #35984),
and S. aureus (ATCC #29213) were obtained from the American Type
Culture Collection (Manassas, VA, USA). For mammalian cell culture, the
following reagents were used as received: 0.01 M PBS pH 7.4
(Sigma-Aldrich), DMEM medium, fetal bovine serum (FBS),
l-glutamine, penicillin, streptomycin, amphotericin B (all
purchased from Life Technologies, Carlsbad, CA, USA), propidium iodide (PI;
Sigma-Aldrich), fluorescein diacetate (FDA; Sigma-Aldrich), lactate
dehydrogenase (LDH) cytotoxicity assay kit II (Abcam, Cambridge, UK), and
trypsin (0.05%, EDTA 0.53 mM, Life Technologies). Cell culture media were
prepared using ultrapurified water supplied by a Milli-Q system (Millipore Co.,
Billerica, MA, USA). NIH/3T3mouse embryonic fibroblasts (ATCC #CRL-1658) from
the American Type Culture Collection were used in these experiments.
Fabrication of THCPSi NPs
THCPSi NPs were fabricated according to the previously reported procedure [25] from p+ type (0.01 to 0.02 Ω cm) silicon wafers by
periodically etching at 50 mA/cm2 (2.2-s period) and
200 mA/cm2 (0.35-s period) in an aqueous 1:1 HF(38%)/EtOH
electrolyte for a total etching time of 20 min. Subsequently, the THCPSi
films were detached from the substrate by abruptly increasing the current
density to electropolishing conditions (250 mA/cm2, 3-s period).
The detached multilayer films were then thermally hydrocarbonized under
N2/acetylene (1:1, volume) flow at 500°C for 15 min and
then cooled down to room temperature under a stream of N2 gas. The
THCPSi membranes (1.3 g) were converted to NPs using wet ball milling
(ZrO2 grinding jar, Pulverisette 7, Fritsch GmbH, Idar-Oberstein,
Germany) in 1 decene (18 mL) overnight. A size separation was performed by
centrifugation (1,500 RCF, 5 min) in order to achieve a narrow particle
size distribution.
Preparation of NO/THCPSi NPs
Sodium nitrite (10 mM) dissolved in 50 mM PBS (pH 7.4) was mixed
with glucose 50 mg/mL. The THCPSi NPs were then added to this buffer
solution at different concentrations (ranging from 0.05 to 0.2 mg/mL).
Subsequently, the suspension was sonicated for 5 min to ensure particle
dispersion and then stirred for 2 h. Upon NO incorporation, the THCPSi NPs
were centrifuged at 8,000 RCF for 10 min for collection. Finally, after
removing the supernatant, the THCPSi NP pellet was dried by heating at 65°C
overnight. The drying temperature was held at 70°C to avoid glucose
caramelization [23,33,34]. An alternative drying procedure, overnight lyophilization (FD1
freeze dryer, Dynavac Co., MA, USA), was also assessed, as described in the text [23].Glucose/THCPSi NPs and sodium nitrite/THCPSi NPs were also prepared following the
same procedure as for the NO/THCPSi NPs but omitting either sodium nitrite or
d-glucose during NP loading, respectively. All prepared NPs
were kept at ambient conditions and were dispersed via sonication for 5 min
in PBS before use.
Pore structure analysis
The pore volume, average pore diameter, and specific surface area of the THCPSi
NPs were calculated from nitrogen sorption measurements on a TriStar 3000
porosimeter (Micromeritics Inc., Norcross, GA, USA).
Scanning electron microscopy
Morphological studies of THCPSi NPs were carried out by means of scanning
electron microscopy (SEM) on a Quanta™ 450 FEG instrument (Hillsboro, OR,
USA) by collecting secondary electrons at 30-kV beam energy under high vacuum of
6 × 10-4 Pa. Energy-dispersive X-ray
spectroscopy (EDX) measurements were performed using a Link 300 ISIS instrument
from Oxford Instruments (detector Si(Li), 30-kV beam energy, resolution
60 eV; Abingdon, Oxfordshire, UK). The samples were prepared by fixing the
NPs to the microscope holder, using a conducting carbon strip. In order to
conduct SEM and EDX analysis of NO/THCPSi NPs treated and untreated with E.
coli, colonies at the desired growth stage were fixed by formaldehyde
(4 v/v%) for 2 h on round graphite disks. After
rinsing twice with PBS, the disks were attached on a SEM holder and were
observed by using the Quanta™ 450 FEG SEM and the Link 300 ISIS EDX
(Oxford Instruments).
Dynamic light scattering
The mean particle size and size distribution of NPs were determined by dynamic
light scattering (DLS; Zetasizer Nano ZS, Malvern Instruments, Malvern, UK). The
analysis was carried out at a temperature of 25°C using NPs dispersed in
ultrapurified water. Every sample measurement was repeated 15 times.
Infrared spectroscopy
Diffuse reflectance infrared Fourier transform (DRIFT) spectra were acquired
using a Thermo Nicolet Avatar 370MCT (Thermo Electron Corporation, Waltham, MA,
USA) instrument. A smart diffuse reflectance accessory was used for all samples
embedded within KBr pellets. The spectra were recorded and analyzed using OMNIC
version 7.3 software (Thermo Electron Corp., Waltham, MA, USA). For each
spectrum, 128 scans were averaged in the range of 4,000 to
800 cm-1 with a resolution of 4 cm-1. In
addition, dipole moments of the chemicals were calculated using the Millsian 2.1
Beta (Millsian, Inc., Cranbury, NJ, USA). Background spectra were blanked using
a suitable clean silicon wafer. All spectra were run in dry air to remove noise
from CO2 and water vapor.
Generation of NO
A calibration curve for NO was obtained by preparing a saturated solution of NO
as described previously by Mesároš et al. [35]. Briefly, 10 mL of PBS (pH 7.4) was degassed using an Ar
purge for 60 min. Subsequently, NO was generated by adding 20 mL of
6 M sulfuric acid slowly to 2 g of sodium nitrite in a twin-neck
round-bottom flask, which was connected via rubber tubing to a Büchner
flask containing KOH solution (to remove NO degradation products,
10% v/v). The Büchner flask was then connected
to the flask containing degassed PBS. The NO gas produced was bubbled through
the degassed PBS (held at 4°C) for 30 min to produce a saturated NO
solution. The solubility of NO in PBS at atmospheric pressure is
1.75 ± 0.02 mM [35-37]. Using Griess reagent [13], our solution was found to have a concentration of 1.87 mM at
37°C.
Colorimetric assay of nitrite
The presence of nitrite compounds can be detected by the Griess reaction, which
results in the formation of a characteristic red pink color. Nitrites react with
sulfanilic acid to form a diazonium salt, which then reacts with
N-alpha-naphthyl-ethylenediamine to form a pink azo dye [38,39]. A calibration curve was prepared using dilutions of sodium nitrite
between 0.43 and 65 μM in PBS (pH 7.4, temperature 37°C)
mixed with equal volumes of the prepared Griess reagent according to the
manufacturer’s instructions. The absorbance of the solutions at
540 nm was measured on a HP8453 PDA UV/VIS spectrophotometer (Agilent,
Santa Clara, CA, USA).
Fluorimetric determination of NO
To detect the release of NO from PSi NP, the DAF-FM assay was used. DAF-FM is
non-fluorescent until it reacts with NO to form a fluorescent benzotrizole.
DAF-FM possesses good specificity, sensitivity (approximately 3 nM) and is
simple to use [23,36]. It does not react with the other nitrogen oxides (i.e.,
NO2- and NO3-) and reactive
oxygen species (i.e., O2- and H2O2) [23].Fluorescence spectra for all samples were acquired using a LS 55
spectrofluorometer (PerkinElmer, Waltham, MA, USA) with slit widths set at
2.5 nm for both excitation and emission; the photomultiplier voltage was
set to 775 V, and a wavelength of 495 nm was used for excitation and
515 nm for emission. In order to prepare an approximate 1 mM stock
DAF-FM solution, 1 mg of DAF-FM was dissolved in 250 μL DMSO and
then the stock solution (10 μL) was mixed with 90 μL PBS
(pH 7.4). Fluorescence was expressed as arbitrary fluorescence units and
was measured at the same instrument settings in all experiments.For the fluorescence-based measurements of NO concentration, a calibration curve
was prepared using dilutions of saturated NO solution in PBS between 0.00 and
1.87 mM in PBS (pH 7.4, 37°C). Fresh DAF-FM stock solution was
added to the PBS and immediately mixed in an Eppendorf tube in the darkness
using a shaker for 2 min and then transferred into a quartz cuvette with a
stopper, and the fluorescence was measured after a 5-min incubation.
Nitric oxide release from NO/THCPSi NPs
The prepared NO/THCPSi NPs (0.1 mg/mL) were added to PBS (1 mL),
sonicated, and mixed using a test tube shaker. After incubation at 37°C for
the sampling interval times specified in the text, the NPs were centrifuged at
12,000 RCF for 5 min and then the supernatant containing the released NO
from the NPs was separated and pre-incubated with 2 μL DAF-FM solution
(approximately 1 mM) for 2 min at room temperature in the darkness on
a test tube shaker (approximately 0.1 RCF). The supernatant containing NO and
DAF-FM was subsequently transferred into a cuvette, and fluorescence intensities
were measured as described above. The amount of the released NO was calculated
using the fluorimetric DAF-FM calibration curve.
Determination of antimicrobial activity
P. aeruginosa, E. coli, and S. aureus were cultured
overnight at 37°C in TSB and diluted to a concentration of 108
colony-forming units per milliliter (CFU/mL) based on turbidity
(OD600) and further diluted to 104 CFU/mL and
1 mL treated with different concentrations of NO/THCPSi NPs or
glucose/THCPSi NPs (control). As a further control, NO/THCPSi NPs
(0.1 mg/mL) were added to 0.5 mL of PBS, sonicated for 5 min and then
incubated for 2 h to remove NO, centrifuged (12,000 RCF for 5 min),
and NO-depleted NO/THCPSi NPs dried at 65°C overnight. Bacteria not treated
with NPs were used as negative controls in each experiment.The NP samples were incubated for 2 h, 4 h (S. aureus; 0.05,
0.1, or 0.2 mg/mL concentration of NPs), and 24 h (P.
aeruginosa, E. coli, and S. aureus; 0.1 mg/mL
concentration of NPs) at 37°C. S. aureus were then serially
diluted and spread-plated on nutrient agar. Bacterial viability was assessed by
counting the number of colonies formed on the agar plate. The colony count was
normalized by considering the untreated colony (negative) as 100% of bacteria
viability. The viability of E. coli and P. aeruginosa after
24 h was determined by turbidity measurements (OD600nm), taking
into account background caused by the NPs themselves.
Effect of NO/THCPSi NPs on established biofilms
The reduction in total viable cells recovered from established S.
epidermidis biofilms treated with NO/THCPSi NPs was compared to the
control biofilms of the same species not treated with the NPs. Glass microscope
slides were cut into pieces with surface areas of 24 mm2. The
glass pieces were cleaned with 70% ethanol and dried. S. epidermidis
was cultured at 37°C in TSB overnight and diluted to
106 CFU/mL. The 106 CFU/mL microbial suspension
was then added to each tube containing the glass slide pieces. The vials
containing bacteria, broth, and glass slide pieces were placed in a 37°C
incubator for biofilm formation. After 24 h, the glass slide pieces were
removed from the nutrient broth, rinsed twice in sterile PBS, and individually
transferred into new Eppendorf tubes containing a fresh suspension 1 mL of
0.1 mg/mL NO/THCPSi NPs and THCPSi NPs (control) in PBS and returned to the
37°C incubator. After 24 h, the tubes containing glass slide pieces
were sonicated in a 125-W ultrasonic cleaner for 5 min to remove the
biofilm-forming cells from the slide. The resulting bacterial suspension was
subjected to serial tenfold dilutions, and 100 μL of appropriate
dilutions was plated onto agar plates, which were then incubated at 37°C
overnight. The total number of colonies that grew on each plate was counted, and
the number of viable biofilm bacteria removed from each slide was
determined.
Mammalian cell viability assay
The cytotoxicity of the NO/THCPSi NPs was evaluated using NIH/3T3 fibroblast
cells. The cells were maintained in DMEM supplemented with 10% FBS and
2 mM l-glutamine, 100 U/mL penicillin,
100 μg/mL streptomycin, and incubated at 37°C with 5%
CO2.All mentioned procedures for the preparation of NO/THCPSi NPs and glucose/THCPSi
NPs were done under sterile conditions within a biological safety cabinet
(Bio-cabinet, Aura 2000, Microprocessor Automatic Control, Firenze, Italy).The NIH/3T3 cells were trypsinized and then seeded into polystyrene 96-well
plates (Nalge Nunc International, Penfield, NY, USA) at a density of
3 × 104 cells/mL and then after 24 h, the
cultured cells were incubated with NO/THCPSi NPs, glucose/THCPSi NPs, and THCPSi
NPs at four different concentrations from 0.05 to 0.2 mg/mL for
48 h.After the incubation period, the culture medium was separated from the cultured
cells and subjected to a LDH assay that was carried out following the
manufacturer’s instructions. Moreover, a FDA-PI assay was performed on the
cultured cells remaining in the wells. The cells were incubated with fresh
medium before adding final concentrations of 15 μg/mL FDA and
5 μM PI for 3 min at 37°C to count the live and dead cells,
respectively, using a fluorescence microscope (Eclipse, Ti-S, Nikon, Tokyo,
Japan) and determine the percentage of live cells. All experiments were repeated
at least three times.
Statistics
For the NO release tests and bactericidal assays conducted in the related media,
n = 3 and the data are expressed as mean
values ± standard deviation. Statistical significance between
populations was determined by one-way ANOVA followed by Tukey’s multiple
comparison post hoc analysis (GraphPad Prism® software). Data from
both the FDA-PI and LDHcytotoxicity assays are presented as mean
values ± standard error of the mean.
Results and discussion
Characterization of NO/THCPSi NPs
THCPSi NPs were prepared using PSi films fabricated by pulsed electrochemical
etching of silicon wafers with (HF; 38%) and ethanol. The preparation and
physicochemical characterization of the THCPSi NPs have been described in detail
elsewhere [24-26]. Briefly, THCPSi NPs were prepared by using wet ball milling of the
multilayer THCPSi films. The described method produced PSi NPs with an average
pore diameter of 9.0 nm, a specific surface area of
202 m2/g, and a pore volume of 0.51 cm3/g. The
NPs were NO-loaded via glucose-mediated reduction of nitrite during incubation
with THCPSi NPs. Two methods of thermal reduction were assessed: one using
lyophilization and one employing heat [23]. The hydrodynamic diameter of the THCPSi NPs and NO/THCPSi NPs was
found to be 137 and 142 nm, respectively, according to dynamic light
scattering measurements (Additional file 1: Figure
S1). The measured zeta (ζ)-potentials of the THCPSi and NO/THCPSi NPs were
-30 and -42 mV, respectively.DRIFT spectroscopy was used to chemically characterize PSi NPs. In order to
scrutinize the nitrite reduction reaction used to prepare the NO/THCPSi NPs,
DRIFT spectra of the prepared THCPSi NPs (control a), glucose/THCPSi NPs
(control b), sodium nitrite/THCPSi NPs (control c), and NO/THCPSi NPs were
obtained (see Figure 1). The DRIFT spectra obtained
from all PSi NPs showed a common set of bands, such as C-H vibration
(2,856 cm-1), related to the thermal hydrocarbonization [40]. The NO/THCPSi NPs spectrum presented a N-O stretching vibration
(dipole moment 0.4344 Debye) at 1,720 cm-1, indicating
entrapment of NO within the NPs [41]. Moreover, in the spectra of the NO/THCPSi NPs and sodium
nitrite/THCPSi NPs, an intense combination band corresponding to
O-N = O around 2,670 cm-1 was observed [42]. The band related to the O-N = O bending vibration
(dipole moment 3.8752 Debye) in the NO/THCPSi NPs is likely to be the result of
unreduced sodium nitrite remaining in the NPs. In addition, the presence of the
O-H stretching vibrations for NO/THCPSi NPs and glucose/THCPSi NPs indicates the
presence of glucose on the NO/THCPSi NPs. A 35% decrease in nitrite band
intensity compared to sodium nitrite/THCPSi NPs (normalized between spectra
based on C-H vibration at 2,856 cm-1) is evidence of the
reduction reaction of nitrite during preparation of NO/THCPSi NPs.
Figure 1
DRIFT absorbance spectra for PSi NPs. (a) THCPSi NPs, (b)
glucose/THCPSi NPs, (c) sodium nitrite/THCPSi NPs, and (d)
NO/THCPSi NPs.
DRIFT absorbance spectra for PSi NPs. (a) THCPSi NPs, (b)
glucose/THCPSi NPs, (c) sodium nitrite/THCPSi NPs, and (d)
NO/THCPSi NPs.
NO release from NO/THCPSi NPs
Sugar-mediated thermal reduction of nitrite-loaded THCPSi NPs produces and
entraps NO inside of THCPSi NPs [18,33]. NO formation is the consequence of chemical acidification and redox
conversion. Upon drying, d-glucose is oxidized, and
correspondingly, nitrite within the pore structure is converted to NO [43]. The dried glucose layer also assists in trapping inside the pores.
The entrapped NO is retained within the pores of the NPs until exposed to
moisture [18,23].The cumulative release of NO from NO/THCPSi NPs was assessed in PBS (pH 7.4)
at 37°C by monitoring conversion of DAF-FM to fluorescein via fluorimetry.
DAF-FM conversion requires NO and does not occur in the presence of other
reactive oxygen/nitrogen species. The results are shown in Figure 2. NO/THCPSi NPs prepared by both heating and lyophilization
protocols were tested. Release of NO from NO/THCPSi NPs occurred predominately
in the first 2 h of the monitoring period. Although NPs created by either
methods displayed the same maximal release of NO into the PBS medium after 2-h
incubation, release profiles obtained using NPs prepared using the
lyophilization protocol showed an initial burst release phase (within the first
30 min). In contrast, glucose/THCPSi NPs, sodium nitrite/THCPSi NPs, PBS,
and sodium nitrite solution controls showed no NO release (Additional file
1: Figure S2), demonstrating that the NO release
indeed only occurs upon nitrite reduction. In reports describing other
NO-releasing mesoporous nanocarriers [9,23], only a short period of continuous release is noted, suggesting that
the NO/THCPSi NPs described here possess a higher capacity for sustained release
of NO.
Figure 2
NO release from NO/THCPSi NPs as a function of time. NO/THCPSi NPs
prepared using the heating protocol (black cross-lines) and the
lyophilization protocol (red empty triangles).
n = 3; mean ± standard deviation
shown.
NO release from NO/THCPSi NPs as a function of time. NO/THCPSi NPs
prepared using the heating protocol (black cross-lines) and the
lyophilization protocol (red empty triangles).
n = 3; mean ± standard deviation
shown.
Antibacterial efficacy of NO/THCPSi NPs
Wound contamination by pathogens such as P. aeruginosa, S.
aureus, and E. coli is responsible for a significant morbidity
load, particularly in burns and immunocompromised patients [8,31,32]. Initial tests of the antibacterial activity of NO/THCPSi NPs
(fabricated by the heating method) were performed against planctonic P.
aeruginosa, E. coli, and S. aureus
(104 CFU/mL for all) treated with 0.1 mg/mL of NPs for
24 h. Compared to the controls (the bacteria cultured without NPs and
bacteria treated with glucose/THCPSi NPs), the NO/THCPSi NPs showed significant
growth inhibition against all three bacteria species tested (see
Figure 3). After the 24-h incubation with
0.1 mg/mL of NO/THCPSi NPs, the bacterial counts of P. aeruginosa,
S. aureus, and E. coli cultures were reduced approximately
1 log in comparison with bacteria cultured in the absence of NPs.
Figure 3
Inhibitory effect of NO/THCPSi NPs (0.1 mg/mL) on bacterial
cultures.E. coli (blue bars), S. aureus
(yellow bars), and P. aeruginosa (green bars) after 24 h
of incubation in TSB medium (37°C, initial bacteria density
104 CFU/mL; n = 3;
mean ± standard deviation shown).
Inhibitory effect of NO/THCPSi NPs (0.1 mg/mL) on bacterial
cultures.E. coli (blue bars), S. aureus
(yellow bars), and P. aeruginosa (green bars) after 24 h
of incubation in TSB medium (37°C, initial bacteria density
104 CFU/mL; n = 3;
mean ± standard deviation shown).Further experiments showed that growth inhibition by NO/THCPSi NPs against
planktonic S. aureus was evident as early as 2 to 4 h after NP
treatment (Figure 4). After 2 h, the bacterial
counts were reduced by 0.52 log compared to the control (bacteria only), and
after 4 h, a further reduction occurred (1.04 log). In contrast,
glucose/THCPSi NPs supported S. aureus proliferation at the same
incubation times. Growth inhibition of S. aureus was sensitive to the
dose of NO/THCPSi NPs applied (Figure 4). When higher
concentrations of NO/THCPSi NPs were applied, the S. aureus bacterial
load decreased by 1.3 log. It should be noted that a by-product of increasing NP
concentration is glucose supplementation, which may be reflected by the increase
in bacterial density in cultures treated with glucose/THCPSi NPs. Cultures
treated with NO/THCPSi NPs, however, showed no such upward trend in bacterial
growth rate, suggesting that the release of NO was able to counter any influence
wrought by additional glucose provided by NO/THCPSi NPs. Therefore, these
results indicate that the NO released form the NO/THCPSi NPs is an effective
antimicrobial agent against medically relevant Gram-positive and Gram-negative
bacteria.
Figure 4
Time-based inhibition of by NO/THCPSi
NPs.S. aureus was treated with glucose/THCPSi NPs (blue
columns) and NO/THCPSi NPs (orange columns) at different NP
concentrations after (a) 2 h and (b) 4 h
(initial bacteria density 104 CFU/mL). Statistically
significant inhibition as compared with control
(*P < 0.05, **P < 0.01;
n = 3; mean ± standard
deviation shown).
Time-based inhibition of by NO/THCPSi
NPs.S. aureus was treated with glucose/THCPSi NPs (blue
columns) and NO/THCPSi NPs (orange columns) at different NP
concentrations after (a) 2 h and (b) 4 h
(initial bacteria density 104 CFU/mL). Statistically
significant inhibition as compared with control
(*P < 0.05, **P < 0.01;
n = 3; mean ± standard
deviation shown).Figure 5 shows the SEM images and EDX spectra of
E. coli treated with NO/THCPSi NPs compared with an untreated
control. Single NPs and NP aggregates were evident in the SEM images on the
bacteria and on the background surface. The presence of the NO/THCPSi NPs on the
surface of the cell membrane of the E. coli was confirmed by the EDX
results, which showed a peak characteristic for Si (Figure 5c).
Figure 5
SEM images and EDX spectra of NO/THCPSi NP-treated . (a) SEM image of NO/THCPSi NP-treated
E. coli, (b) SEM image of the E. coli only,
(c) EDX spectrum of NO/THCPSi NP-treated E. coli,
and (d) EDX spectrum of untreated E. coli as a control.
EDX analysis performed on bacterial surface (yellow overlay). NPs on the
bacterial surface and settled on the background are indicated by red
arrows.
SEM images and EDX spectra of NO/THCPSi NP-treated . (a) SEM image of NO/THCPSi NP-treated
E. coli, (b) SEM image of the E. coli only,
(c) EDX spectrum of NO/THCPSi NP-treated E. coli,
and (d) EDX spectrum of untreated E. coli as a control.
EDX analysis performed on bacterial surface (yellow overlay). NPs on the
bacterial surface and settled on the background are indicated by red
arrows.
Anti-biofilm efficacy of NO/THCPSi NPs
S. epidermidis biofilms were exposed to the NO/THCPSi NPs at a
concentration of 0.1 mg/mL and showed a 0.28 log (47%) reduction in total
viable cells compared to the control samples (bacteria only). THCPSi NPs that
were not loaded with NO applied at the same concentration produced a negligible
reduction in the biofilm density, indicating that the NO released from the
prepared NO/THCPSi NPs was the primary cause of any antimicrobial action. In
comparison with the high doses of NO donorsilica NPs reportedly required for
the treatment of S. epidermidis biofilms [22], the sugar-mediated NO/THCPSi NPs showed effective biofilm reduction
at a fractional dose.
Cytotoxicity of NO/THCPSi NPs to NIH/3T3 fibroblast cells
The biocompatibility of THCPSi NPs has been previously reported by Santos and
co-workers [25,28], where cytotoxicity, oxidative, and inflammatory responses were
studied for a variety of mammalian cell lines. The toxicity of NO/THCPSi NPs,
glucose/THCPSi NPs, and THCPSi NPs at different concentrations (0.05 to
0.2 mg/mL) over 48 h was evaluated using the NIH/3T3 cell line, which
is one of the most commonly used fibroblast cell lines and often used as a model
for skin cells. Two viability assays were used for toxicity studies: LDH and
fluorescein diacetate-propidium iodide (FDA-PI). As shown in Figure 6, the results from the LDH assay showed well over 90%
viability for all NP types up to 0.1 mg/mL. However, increasing the
concentration of NO/THCPSi NPs to 0.2 mg/mL reduced the viability of
NIH/3T3 cells to 92%. In contrast, the viability of fibroblast cells incubated
with glucose/THCPSi NPs and THCPSi NPs at 0.15 and 0.2 mg/mL remained over
95%. The results of the FDA-PI assay (Additional file 1: Figure S3) were consistent with those obtained using the LDH
assay.
Figure 6
Toxicity of the NPs to NIH/3T3 fibroblasts using the LDH assay after
48-h incubationc NO/THCPSi NPs (red bars), glucose/THCPSi NPs
(blue bars), and THCPSi NPs (yellow bars). Viability measures normalized
to no NP control samples (n = 3;
mean ± standard deviation shown).
Toxicity of the NPs to NIH/3T3 fibroblasts using the LDH assay after
48-h incubationc NO/THCPSi NPs (red bars), glucose/THCPSi NPs
(blue bars), and THCPSi NPs (yellow bars). Viability measures normalized
to no NP control samples (n = 3;
mean ± standard deviation shown).The cytotoxicity of THCPSi NPs has been reported to be concentration dependent [25,27], and increased concentrations of NO/THCPSi NPs did raise
cytotoxicity. However, the cytotoxicity of THCPSi NPs on fibroblast cells is
much less than observed for silica NPs, silver NPs, and other clinical
antiseptic wound treatments [3,11,44,45]. We note that dosage optimization (e.g., concentration of
0.1 mg/mL) enables a balance between high antibacterial efficacy and low
toxicity towards mammalian cells present in a wound environment to be
achieved.
Conclusions
The present work demonstrates the capacity of THCPSi NPs to be loaded with NO by
utilizing the sugar-mediated thermal reduction of nitrite. These NO/THCPSi NPs
possess the capacity to deliver NO at therapeutic levels in a more sustained manner
than previously demonstrated using NO-releasing NPs. NO delivered from the NPs was
effective at killing pathogenic P. aeruginosa, E. coli, and S.
aureus after only 2 h of incubation. After 24 h, the bacterial
load was reduced by approximately 1 log. In addition, NO/THCPSi NPs showed
effectiveness at inhibiting the growth of biofilm-based microbes. The NO/THCPSi NPs
demonstrated a 47% reduction in S. epidermidis biofilm viability compared
to the control samples. On the other hand, NIH/3T3mouse fibroblasts incubated with
the same concentration of NO/THCPSi NPs for 48 h maintained high cell
viability. In summary, our results suggest that NO/THCPSi NPs are useful as a
nanocarrier for NO release to treat bacterial infections in wounds. Future studies
will focus on enhancing NO release and identifying the interactions between
NO/THCPSi NPs and bacterial cell membranes.
The authors declare that they have no competing interests.
Authors’ contributions
NHV, MHK, JS, and KV conceived and designed the experiments. MHK, AC, and BD
performed the experiments. MHK, AC, FJH, BD, and NHV analyzed the data. MHK, AC, BD,
FJH, SJPM, EM, JS, KV, and NHV wrote the paper. All authors read and approved the
final manuscript.
Additional file 1: Figure S1
Representative scanning electron microscope (SEM) image of THCPSi NPs (a)
and DLS size distribution of THCPSi NPs (b). Figure S2.
fluorescence detection of NO released from NO/THCPSi NPs. (a)
Calibration curve obtained by adding aliquots of saturated NO solution
(1.87 mM) to PBS containing DAF-FM indicator. (b) NO detection from
NO/THCPSi NPs, glucose/THCPSi NPs (control), sodium nitrite/THCPSi NPs
(control), sodium nitrite (control), and PBS (control) prepared using
the heating protocol after 2 h of the release process at 37°C.
Figure S3. cytotoxicity of (A) NO/THCPSi NPs, (B)
glucose/THCPSi NPs, (C) THCPSi NPs, and (D) no treatment control towards
NIH/3T3 cells as measured by FDA-PI assay after 48 h. The roman
numbers represent the different concentrations of the NPs (I
0.05 mg/mL, II 0.1 mg/mL, III 0.15 mg/mL, and IV
0.2 mg/mL).Click here for file
Authors: J S Pollock; U Förstermann; J A Mitchell; T D Warner; H H Schmidt; M Nakane; F Murad Journal: Proc Natl Acad Sci U S A Date: 1991-12-01 Impact factor: 11.205
Authors: Margaret A Fonder; Gerald S Lazarus; David A Cowan; Barbara Aronson-Cook; Angela R Kohli; Adam J Mamelak Journal: J Am Acad Dermatol Date: 2008-02 Impact factor: 11.527
Authors: Evan M Hetrick; Jae Ho Shin; Nathan A Stasko; C Bryce Johnson; Daniel A Wespe; Ekhson Holmuhamedov; Mark H Schoenfisch Journal: ACS Nano Date: 2008-02 Impact factor: 15.881
Authors: H Kojima; N Nakatsubo; K Kikuchi; S Kawahara; Y Kirino; H Nagoshi; Y Hirata; T Nagano Journal: Anal Chem Date: 1998-07-01 Impact factor: 6.986